Eutropics wins NCI contract
Eutropics will provide its BH3 profiling diagnostic assay to the NCI.
Eutropics Pharmaceuticals has been awarded a new contract to provide companion diagnostic services to the National Cancer Institute (NCI) in the US.
The agreement, signed through the institute's Small Business Initiative Research programme, will see it using its BH3 profiling diagnostic assay for treatments used in the management of patients with acute myelogenous leukaemia (AML).
The assay provides diagnostic help that can be used to inform the use of several different therapies and is currently being tested as a tool to be used alongside more experimental treatments currently in development.
It uses a biomarker that provides an understanding of whether or not cancer cells will be capable of responding to certain treatments, making it a crucial tool in deciding when to use certain treatments and which should be avoided.
"There is a very good likelihood that this BH3 profiling technology will provide an important guiding tool for treating AML," said Dr Michael Andreeff, chief of molecular hematology at MD Anderson Cancer Center and scientific advisor to Eutropics.
"We are all looking forward to its validation in the clinical studies proposed in this contract."
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.